enGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says

MT Newswires Live06-18

enGene (ENGN) is experiencing "reduced confidence" from physicians that the company's LEGEND clinical trial to treat patients with non-muscle invasive bladder cancer would support significant adoption of detalimogene, Morgan Stanley analysts wrote Thursday in a note to clients.

"We still believe that detalimogene's safety and simple handling/administration could increase its appeal in some community practices, but detalimogene's competitiveness on efficacy/durability likely negatively impacts commercial prospects," the analysts wrote.

The analysts said expert feedback has indicated that detalimogene's current durability profile is "simply not competitive," and that it may be "relegated to a late position in the sequencing order."

Morgan Stanley downgraded the stock to underweight from equal-weight. enGene has an average rating of hold and a mean price target of $6.85, according to analysts polled by FactSet.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644125085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644125085","market":"us","top_or_hot":-1,"title":"enGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> enGene (ENGN) is experiencing \"reduced confidence\" from physicians that the company's LEGEND clinical trial to treat patients with non-muscle invasive bladder cancer would support significant adoption of detalimogene, Morgan Stanley analysts wrote Thursday in a note to clients.</p><p>\"We still believe that detalimogene's safety and simple handling/administration could increase its appeal in some community practices, but detalimogene's competitiveness on efficacy/durability likely negatively impacts commercial prospects,\" the analysts wrote.</p><p>The analysts said expert feedback has indicated that detalimogene's current durability profile is \"simply not competitive,\" and that it may be \"relegated to a late position in the sequencing order.\"</p><p>Morgan Stanley downgraded the stock to underweight from equal-weight. enGene has an average rating of hold and a mean price target of $6.85, according to analysts polled by FactSet.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>enGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nenGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-18 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> enGene (ENGN) is experiencing \"reduced confidence\" from physicians that the company's LEGEND clinical trial to treat patients with non-muscle invasive bladder cancer would support significant adoption of detalimogene, Morgan Stanley analysts wrote Thursday in a note to clients.</p><p>\"We still believe that detalimogene's safety and simple handling/administration could increase its appeal in some community practices, but detalimogene's competitiveness on efficacy/durability likely negatively impacts commercial prospects,\" the analysts wrote.</p><p>The analysts said expert feedback has indicated that detalimogene's current durability profile is \"simply not competitive,\" and that it may be \"relegated to a late position in the sequencing order.\"</p><p>Morgan Stanley downgraded the stock to underweight from equal-weight. enGene has an average rating of hold and a mean price target of $6.85, according to analysts polled by FactSet.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENGN","symbol_name":"ENGENE HOLDINGS INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644125085","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644125085","pubTimestamp":1781786706,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"enGene (ENGN) is experiencing \"reduced confidence\" from physicians that the company's LEGEND clinical trial to treat patients with non-muscle invasive bladder cancer would support significant adoption","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ENGN":"ENGENE HOLDINGS INC","BK4139":"生物科技"},"translate_title":"摩根士丹利表示，enGene Detalimogene的耐用性“没有竞争力”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENGN":1},"content_text":"enGene (ENGN) is experiencing \"reduced confidence\" from physicians that the company's LEGEND clinical trial to treat patients with non-muscle invasive bladder cancer would support significant adoption of detalimogene, Morgan Stanley analysts wrote Thursday in a note to clients.\"We still believe that detalimogene's safety and simple handling/administration could increase its appeal in some community practices, but detalimogene's competitiveness on efficacy/durability likely negatively impacts commercial prospects,\" the analysts wrote.The analysts said expert feedback has indicated that detalimogene's current durability profile is \"simply not competitive,\" and that it may be \"relegated to a late position in the sequencing order.\"Morgan Stanley downgraded the stock to underweight from equal-weight. enGene has an average rating of hold and a mean price target of $6.85, according to analysts polled by FactSet.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644125085","isCrawlerRequest":true}